首页> 外文期刊>Human Genetics >Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics.
【24h】

Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics.

机译:根据在澳大利亚家庭癌症诊所就诊的多例乳腺癌家庭估计的BRCA1和BRCA2生殖系突变的类型和部位,乳腺癌的平均年龄特定累积风险。

获取原文
获取原文并翻译 | 示例
           

摘要

If the risk of disease is not the same for all germline mutations in a given gene, or if there are other familial modifiers of risk in carriers, then family-history-based estimates of average risk for detected mutations in that gene will depend on how carriers are sampled. Risk may also depend on the site or type of mutation. We studied 51 families with strong histories of breast cancer who attended Australian family cancer clinics and in which a germline mutation in BRCA1 or BRCA2 had been identified (28 and 23 families, respectively). Breast cancer risk in carriers was estimated under maximum likelihood theory, using information from all family members including those not tested, with adjustment for ascertainment by conditioning on genotype of the proband and family phenotype. The average cumulative risk of breast cancer for mutations in either BRCA1 or BRCA2 was 27% (95% confidence interval 16-43%) to age 50 and 64% (44-83%) to age 70. When grouped, the incidence in carriers was on average 17 (10-30) times that in non-carriers, independent of gene or mutation type (hazard ratios: 11 (4-29) for BRCA1, 23 (12-43) for BRCA2 (P for difference = 0.23); 13 (6-29) for protein-truncating mutations, 30 (9-104) for missense mutations and 30 (10-90) for splice-site mutations). For missense mutations, this was equivalent to a cumulative risk to age 70 of 83% (40-100%) and was due in part, but not totally, to the missense mutations 300 T>G in BRCA1 and 4486 G>T in BRCA2, which were individually found to be associated with high risk (P<0.001). Mutations in the central region of BRCA1 may be associated with a lower risk. The issue of the pathogenicity of specific variants may be addressed analytically providing there are one or more suitably informative families with that mutation.
机译:如果给定基因中所有种系突变的疾病风险都不相同,或者携带者中存在其他家族风险修饰因子,则基于家族史的对该基因中检测到的突变平均风险的估计将取决于载波被采样。风险还可能取决于突变的部位或类型。我们研究了在澳大利亚家庭癌症诊所就诊的具有悠久乳腺癌史的51个家庭,其中已鉴定出BRCA1或BRCA2的种系突变(分别为28和23个家庭)。携带者患乳腺癌的风险是根据最大可能性理论,使用所有家庭成员(包括未接受测试的家庭成员)的信息进行估计的,并通过对先证者的基因型和家庭表型进行条件确定来进行调整。到50岁时,BRCA1或BRCA2中发生突变的乳腺癌的平均累积风险为27%(95%置信区间16-43%)和70岁至64%(44-83%)。分组后,携带者的发生率分别是非携带者的17倍(10-30)倍,而与基因或突变类型无关(危险比:BRCA1为11(4-29),BRCA2为23(12-43)(差异P = 0.23) ;蛋白截短突变为13(6-29),错义突变为30(9-104),剪接位点突变为30(10-90)。对于错义突变,这相当于70岁时的累积风险为83%(40-100%),部分但并非完全是由于BRCA1中的错义突变300 T> G和BRCA2中的错失突变4486 G> T ,这些被单独发现与高风险有关(P <0.001)。 BRCA1中心区域的突变可能与较低的风险相关。只要存在一个或多个具有该突变的信息丰富的家族,就可以通过分析方式解决特定变体的致病性问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号